You are here

Home » Content

KRONİK PERİODONTİTİSTE BAŞLANGIÇ PERIODONTAL TEDAVİYE EK OLARAK YARA ÖRTÜCÜ AJAN (PERIOFILM®) UYGULAMASININ KLİNİK VE BİYOKİMYASAL ETKİLERİNİN İNCELENMESİ

CLINICAL AND BIOCHEMICAL EVALUATION OF PERIOFILM® AS AN ADJUNCT TO NON-SURGICAL PERIODONTAL THERAPY

Journal Name:

  • İstanbul Üniversitesi Diş Hekimliği Fakültesi Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The objective of this study was to evaluate the clinical and biochemical effects of local sodium piperacillin (Periofihn®) therapy used as an adjunct to scaling and root planning (SRP) in chronic periodontitis patients. A total of 20 patients with probing depth (PD) > 5mm and gingival index (GI) > 2 in at least 2 single-rooted teeth were included. Group 1 received SRP, whereas group 2 received SRP + Periofilm® application. The clinical and biochemical parameters were monitored over a period of 90 days. At 0. and 90. days, plaque index, GI, PD, relative attachment level and gingival recession were measured. At the same days gingival crevicular fluid (GCF) samples were also collected After determination of GCF volume matrix metalloproteinase-8 (MMP-8) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) levels were measured by ELISA.At 90 days in SRP and SRP+Periofılm® groups, mean PD reduction of 2.2±0.8 mm and 2.28±0.68 mm, attachment gain of 1.49±0.84 mm and 1.71Ü.00 mm, recession of 0.71±0.58 mm and 0.56±0.92 mm were found respectively (p<0.05). All periodontal sites treated with either SRP or SRP+Periofılm® revealed a decrease in MMP-8 concentration and an increase in T1MP-1 concentration which was parallel to the clinical parameters (p<0.001). Considering all parameters, no significant intergroup changes were found between the groups (p>0.05). Under the light of our findings, it can be concluded that initial periodontal therapy is essential in consolidating clinical and biochemical improvements. Both treatment groups responded to therapy with similar resolution of infection reflected to clinical and biochemical parameters.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışmada, kronik periodontitisli (KP) hastalarda başlangıç periodontal tedaviye destek olarak kullanılan, lokal sodyum piperasilin (Periofilm®) uygulamasının klinik ve biyokimyasal parametreler üzerindeki etkisi incelendi. Çalışmaya sondalama derinliği (SD) > 5 mm ve gingival indeksi (Gİ) > 2 olan en az 2 tek köklü dişi bulunan, 20 KP'li hasta dahil edildi. 1. gruba diş yüzeyi temizliği ve kök yüzeyi düzleştirmesi (SRP), 2. gruba SRP'ye ek olarak Periofilm® (SRP+Periofılm®) uygulandı. 0. ve 90. günde plak indeksi, Gİ, SD, rölatif ataşman ve rölatif dişeti kenarı seviyesi ölçüldü ve dişeti oluğu sıvısı (DOS) örnekleri toplandı. Biyokimyasal analizler için toplanan DOS örnekleri içerisinde matriks metalloproteinaz-8 (MMP-8) ve matriks metalloproteinaz doku inhibitörü-1 (TIMP-1) seviyeleri ELI S A yöntemi ile değerlendirildi. SRP ve SRP+Periofılm® aruülannın örnekleme bökelerinde 90 aünde klinik üarametrelerde baslanaıca aöre anlamlı ivilesme saptandı fp<0 05) ve sırasıyla 2.2±0.8 mm ve 2 28*0.68 mm SD azalması, 1.49±0.84 mm ve 1 71±1 mm ataşman kazancı, 0.71*0 58 mm ve 0 56±0 92 mm dişeti çekilmesi tespit edildi DOS MMP-8 ve TTMP-l konsantrasyon değerleri SRP ve SRP+Periofılm® gruplarında klmık parametrelere paralel olarak 90 günde başlangıca göre anlamlı değişim gösterdi (p<0 001) Tüm parametrelerde gruplar arası karşılaştırmada istatistiksel olarak anlamlı bir farklılık bulunmadı fp>0 05)' Başlangıç periodontal tedaviye ek olarak "kullanılan Periofilm® in klinik ve biyokimyasal bulgulara herhangi bir ilave katkısının olmadığı saptandı
FULL TEXT (PDF): 
PDF icon arastirmax-kronik-periodontitiste-baslangic-periodontal-tedaviye-ek-olarak-yara-ortucu-ajan-periofilmr-uygulamasinin-klinik-biyokimyasal-etkilerinin-incelenmesi.pdf
  • 3
49
57
  • Turkish

REFERENCES

References: 

1.
Offenbacher S. Periodontal diseases: Pathogenesis. Ann Periodontal, 1996; 11: 821¬78.
2. Loesche WJ, Syed SA, Schmidt E, Morrison EC. Bacterial profiles of subgingival plaques in periodontitis. J Periodontal, 1985; 56 (8): 447¬56.
3. Mousques T, Listgarten MA, Philips RW. Effect of scaling and root planing on the composition of human subgingival microbial flora. J Periodont Res, 1980; 15: 144-151.
4. Birkedal-Hansen H. Role of matrix metelloproteinases in human periodontal diseases. J Periodontal, 1993; 64 (5 Suppl): 474-84.
5. Uitto VJ, Overall CM, McCulloch C. Proteolytic host cell enzymes in gingival crevice fluid. Periodontal 2000, 2003; 31: 77¬104.
6. Ryan ME, Golub LM. Modulation of matrix metelloproteinase activities in periodontitis as a treatment strategy. Periodontal 2000, 2000; 24: 226-38.
7. Ryan ME, Ramamurthy S, Golub LM. Matrix metelloproteinases and their inhibition in periodontal treatment. Curr Opin Periodontal, 1996; 3: 85-96.
8. Reynolds JJ, Meikle MC. Mechanisms of connective tissue matrix destruction in periodontitis. Periodontal 2000, 1997; 14: 144¬57.
9. Palosaari H, Wahlgren J, Larmas M, Rönkâ H, Sorsa T, Salo T, Tjâderhane L. The expression of MMP-8 in human odontoblasts and dental pulp cells is down-regulated by TGF-betel. J Dent Res, 2000; 79 (1): 77-84.
10. Golub LM, Suomalainen K, Sorsa T. Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent, 1992; 2: 80-90.
11. Golub LM, Sorsa T, Lee HM, Ciancio S, Sorbi
Kronik Periodontitiste Başlangıç Periodontal Tedaviye Ek Olarak Yara Örtücü Ajan Uygulaması
55
D, Ramamurthy NS, Gruber B, Salo T, Konttinen YT. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol, 1995; 22 (2): 100-109.
12. Golub LM, Lee HM, Greenwald RA, Ryan ME, Sorsa T, Salo T, Giannobile WV. A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis Inflamm Res 1997- 46 (8V 310-319. ' ' '
13. Lee W, Aitken S, Sodek J, McCulloch CA. Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in vivo: role of active enzyme in human periodontitis J Periodontal Res 1995¬30 (1): 23-33. ' ' '
14. Ingman T, Tervahartiala T, Ding Y, Tschesche H, Haerian A, Kinane DF, Konttinen YT, Sorsa T. Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients. J Clin Periodontol, 1996; 23 (12): 1127-1132.
15. Ingman T, Sorsa T, Lindy O, Koski H, Konttinen YT. Multiple forms of gelatinases/type IV collagenases in saliva and gingival crevicular fluid of periodontitis patients. J Clin Periodontol, 1994; 21 (1): 26¬31.
16. Chen HY, Cox SW, Eley BM, Mântylâ P, Rönkâ H, Sorsa T. Matrix metalloproteinase-8 levels and elastase activities in gingival crevicular fluid from chronic adult periodontitis patients. J Clin Periodontol, 2000; 27 (5): 366¬369.
17. Mancini S, Romanelli R, Laschinger CA, Overall CM, Sodek J, McCulloch CA. Assessment of a novel screening test for neutrophil collagenase activity in the diagnosis of periodontal diseases J Periodontol 1999-70 (11):
1292-302.
18. Kiili M, Cox SW, Chen HY, Wahlgren J, Maisi P, Eley BM, Salo T, Sorsa T. Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult
periodontitis: molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue. J Clin Periodontol, 2002; 29 (3): 224-232.
19. Sorsa T, Mântylâ P, Rönkâ H, Kallio P, Kallis GB, Lundqvist C, Kinane DF, Salo T, Golub LM, Teranen O, Tikanoia S. Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. Ann N Y Acad Sci, 1999; 30: 130-40.
20. Romanelli R, Mancini S, Laschinger C, Overall CM, Sodek J, McCulloch CA. Activation of neutrophil collagenase in periodontitis. Infect Immun, 1999; 67 (5): 2319-26.
21. Tervahartiala T, Pirilâ E, Ceponis A, Maisi P, Salo T, Tuter G, Kallio P, Tornwall J, Srinivas R, Konttinen YT, Sorsa T. The in vivo expression of the collagenolytic matrix metalloproteinases (MMP-2, -8, -13, and -14) and matrilysin (MMP-7) in adult and localized liuvenile periodontitis J Dent Res 2000- 79 (12): 1969-77.
22. Kinane DF, Darby IB, Said S, Luoto H, Sorsa T, Tikanoja S, Mântylâ P. Changes in gingival crevicular fluid matrix metalloproteinase-8 levels during periodontal treatment and maintenance. J Periodontal Res, 2003; 38 (4): 400-04.
23.
Tüter G, Kurtiş B, Serdar M, Yücel A, Ayhan E, Karaduman B, Ozcan G. Effects of phase I periodontal treatment on gingival crevicular fluid levels of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1. J Clin Periodontol, 2005; 32 (9): 1011-5.
24. Kumar MS,' Vamsi G, Sripriya R, Sehgal PK. Expression of matrix metalloproteinases (MMP-8 and -9) in chronic periodontitis patients with and without diabetes mellitus. J Periodontol, 2006; 77 (11): 1803-8.
25. Haerian A, Adonogianaki E, Mooney J, Docherty JP, Kinane DF. Gingival crevicular stromeiysin, collagenase and tissue inhibitor of matrix metalloproteinase levels in healthy and diseased sites. J Clin Periodontol, 1995; 22: 505-09.
56
Şebnem Dirikanİpçi, Gökser Çakar Gürlüman, Nazlı Menemencioğlu, Bahar Eren Kuru, ÜlküNoyan, Selçuk Yılmaz
26. Kubota T, Matsuki Y, Nomura T, Hara K. In situ hybridization study on tissue inhibitors of metalloproteinases (TIMPs) mRNA-expressing cells in human inflamed gingival tissue. J Periodontites, 1997; 32: 467-72.
27. Noyan Ü, Yılmaz S, Kuru B, Kadir T, Acar O, Büğet E. A clinical and microbiological evaluation of systemic and local metronidazole delivery in adult periodontitis patients. J Clin Periodontol, 1997; 24: 158-65.
28. Badersten A, Nilveus R, Egelberg J. Effect of non-surgical periodontal therapy. I. Moderately advanced periodontitis. J Clin Periodontol, 1981; 8: 57-72.
29. Rams TE, Slots J. Local delivery of antimicrobial agents in the periodontal pocket. Periodontol 2000, 1996; 10: 139-159.
30. Quirynen M, De Soete M, Dierickx K, van Steenberghe D. The intra-oral translocation of periodontopathogens jeopardizes the outcome of periodontal therapy. J Clin Periodontol, 2001; 28: 499-507.
31. Slots J. Selection of antimicrobial agents in periodontal therapy. J Periodontal Res, 2002; 37 (5): 389-98.
32. Ciancio SG. Nonsurgical chemical periodontal therapy. Periodontol 2000, 1995; 9: 27-37.
33. Visconti PC, Capuano A, Parrini S. Local antibiotic therapy with sodium piperacillin. Dental Cadmods, 2003; 04: 73-81.
34. Novak MJ. Classification of diseases and conditions affecting the periodontium. Carranza FA Clinical Periodontology. 10. bs., USA : W.B. Saunders Co., 2009, s: 100-109.
35. Armitage GC. Development of classification system for periodontal diseases and conditions. Ann Periodontol, 1999; 4: 1-6.
36. Joyston-Bechal S, Smales FC, Duckworth R. A follow-up study 3 years after metronidazole therapy for chronic periodontal disease. J Clin Periodontol, 1986; 13: 944- 949.
37. Africa CW, Parker JR, Reddy J. Study of the cultivable flora of subgingival plaque of patients with severe periodontitis. J Dent Assoc S Afr, 1985; 40(1): 11-4.
38. Haffajee AD, Cugini MA, Dibart S, Smith C, Kent RL Jr, Socransky SS. Clinical and microbiological features of subjects with adult periodontitis who responded poorly to scaling and root planing. J Clin Periodontol, 1997; 24 (10): 767-76.
39. O'Conner BC, Newman HN, Wilson M. Susceptibility and resistance of plaque bacteria to minocycline. J Periodontol, 1990; 61: 228¬33.
40. Darveau RP, Tanner A, Page RC. The microbial challenge in periodontitis. Periodontol 2000, 1997; 14: 12-32.
41. Lamont PJ, Oda D, Persson RE, Persson GR. Interaction of Porphyromonas gingivalis with gingival epithelial cellsmaintained in culture. Oral Microbiol Immunol, 1997; 7: 364-367.
42. Rifkin BR, Vernillo AT, Golub LM. Blocking periodontal disease progression by inhibiting tissue destructive enzymes: a potential therapeutic role for tetracyclines and their chemically modified analogs. J Periodontol, 1993; 64 (8 Suppl): 819-27.
43. Slots J, Rams TE. Antibiotics in periodontal therapy: advantages and disadvantages. J Clin Periodontol, 1990; 17 (7): 479-93.
44. Sutter VL, Jones JM, Ghoniem AT. Antimicrobial susceptibilities of bacteria associated with periodontal disesae. Antimicrob Agants Chemother, 1983; 23: 483-486.
45. Walker CB, Pappas JD, Tyler KZ, Cohen S, Gordon JM. Antibiotic susceptibilities of periodontal bacteria. In vitro susceptibilities to eight antimicrobial agents. J Periodontol, 1985; 56 (suppl): 67-74.
Kronik Periodontitiste Başlangıç Periodontal Tedaviye Ek Olarak Yara Örtücü Ajan Uygulaması
57
46. Walker CB, Tyler KT, Low SB, King CJ. Penicillin degrading enzymes in sites associated with adult periodontitis. Oral Microbiol Immunol, 1987; 2: 129-31.
47. Layton JM, Walker CB, Pappas JD. Gingival fluid level of amoxicillin and its MIC's for periodontal bacteria. J Dent Res, 1983; 62 (spec, issue): 290.
48. Kinder SA, Holt SC, Kornman KS. Penicillin resistance in the subgingival microbiota associated with adult periodontitis. J Clin Microbiol, 1986; 23: 1127-1133.
49. Valdes MV, Lobbins PM, Slots J. Beta-lactamase producing bacterian in the human oral cavity. J Oral Pathol, 1982; 11: 58-63.

Thank you for copying data from http://www.arastirmax.com